Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression

Journal of Oral Pathology and Medicine

Volumn 27, Issue 8, 1998, Pages 367-375

  Van Oijen, M G C T ^a   Tilanus, M G J ^a   Medema, R H ^a   Slootweg, P J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

BrdU; Cyclin D1; Differentiation; Head and neck cancer; p21 (Waf1 Cip1); p53; Proliferation

Indexed keywords

EID: 0032167646     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.1998.tb01969.x     Document Type: Article

References (40)

1. PAPADIMITRAKOPOULOU VA, SHIN DM, HONG WK. Molecular and cellular bio-markers for field cancerization and multistep process in head and neck tumorigenesis. Cancer Metastasis Rev 1996; 15: 53-76.
2. HARRIS CC. Structure and function of the p53 tumor suppressor gene; clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-55.
3. BRENNAN JA, BOYLE JO, KOCH WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med 1995; 332: 712-7.
4. KIURU A, SERVOMAA K, GRÉNMAN R, PULKKINEN J, RYTÖMAA T. p53 mutations in human head and neck cancer cell lines. Acta Otolaryngol 1997; Suppl 529: 237-40.
5. HOSOWAKA Y, ARNOLD A. Cyclin D1/ PRAD1 as a central target in oncogenesis. J Lab Clin Med 1996; 127: 246-55.
6. SCHUURING E, VERHOEVEN E, MOOI WJ, MICHALIDES RJAM. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992; 7: 355-61.
7. BARTKOVA J, LUKAS J, MüLLER H, STRAUSS M, GUSTERSON B, BARTEK J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995; 55: 949-56.
8. GARTEL AL, SERFAS MS, TYNER AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996; 213:138-49.
9. ADAMS PD, SELLER WR, SHARMA SK, WU AD, NALIN CM, KAELIN JR WG. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 1996; 16: 6623-33.
10. ZHANG H, HANNON GJ, BEACH D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994; 8: 1750-8.
11. HEINZEL PA, BALKARAM P, BERNARD H-U. Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer 1996; 68: 420-3.
12. SHIOHARA M, EL-DEIRY WS, WADA M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-4.
13. MOUSSES S, OZCELIK H, LEE PD, MALKIN D, BULL SB, ANDRULIS IL. Two variants of the Cip/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 1995; 4: 1089-92.
14. CIP1 in muscle and other terminally differentiating cells. Science 1995; 267. 1024-7.
15. WAFI/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-9.
16. SJÖRGEN S, INGANAS M, NORBERG T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-82.
17. LEHMAN TA, BENETT WP, METCALF RA, et al. p53 mutations, ras mutations, and p53 heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991; 51: 4090 6.
18. JONES MH, NAKAMURA Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer 1992; 5: 89-90.
19. VAN OIJEN MGCT, MEDEMA RH, SLOOTWEG PJ, RIJKSEN G. Positivity of the proliferation marker Ki-67 in non-cycling cells. Am J Clin Pathol 1998; 110: 24-31.
20. Ross W, HALL PA. Ki-67: from antibody to molecule to understanding. J Clin Pathol Mol Pathol 1995; 48: M113-7.
21. WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol 1997; 183: 156-63.
22. CIP1/WAF1 protein accumulation in head-and-neck cancer. Int J Cancer 1997; 74: 383-9.
23. WAF1/CIP1/SD1 in differentiating human leukemic cells. J Clin Invest 1995; 95: 973-9.
24. Cip1/WAF1/Sdi1. J Pathol 1997; 183: 134-40.
25. SHEIKH MS, LI X-S, CHEN J-C, SHAO Z-M, ORDONEZ JV, FONTANA JA. Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 1994; 9: 3407-15.
26. MARCHETTI A, DOGLIONI C, BARESCHI M, et al. p21 mRNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996; 12: 1319-24.
27. MATSUSHITA K, KOBAYASHI S, KATO M, et al. Reduced mRNA expression level of p21CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. Int J Cancer (Pred Oncol); 1996; 69: 259-64.
28. JUNG JM, BRUNER JM, RUAN S, et al. Increased level of p21WAF1/Cip1 in human brain tumors. Oncogene 1995; 11: 2021-8.
29. DIOGLIONT C, PELOSIO P, LAURINO L, et al p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation J Pathol 1996; 179: 248-53.
30. LI Y, JENKINS CW, NICHOLS MA, XIONG Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994; 9: 2261-8.
31. MELHELM MF, LAW JC, EL-ASHMAWY L, et al. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995; 146: 1170-7.
32. MIDGLEY CA, LANE DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on mdm2 binding. Oncogene 1997; 15: 1179-89.
33. KLIJANIENKO J, MICHEAU C, CARLU C, CAILLAUD JM. Significance of keratin 13 and 6 expression in normal, dysplastic and malignant squamous epithelium of pyriform fossa. Virchows Arch A Pathol Anat Histopathol 1989; 416: 121-4.
34. MICHIELI P, CHEDID D, LIN D, PIERCE J, MERCER W, GIVOL D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994; 54: 3391-5.
35. DATTO M, Li Y, PANUS J, HOWE D, XIONG Y, WANG X. Transforming growth factor β induces the cyclin-dependent kinase inhibitor .p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995; 92: 5545-9.
36. YAN G-Z, ZIFF EB. Nerve growth factor induces transcription of the p21 WAF1/ CIP1 and cyclin D1 genes in PC12 cells by activating the Sp1 transcription factor J Neurosci 1997; 17: 6122-32.
37. HALEVY O, NOVITCH BG, SPICER DB, et al. Correlation of terminal cell arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267: 1018-21.
38. KAGHAD M, BONNET H, YANG A, et al Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-19.
39. HIYAMA H, IAVARONE A, LABAER J, REEVES S. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 1997; 14: 2533-2.
40. GAO CY, ZELENKA PS. Cyclins, cyclin-dependent kinases and differentiation. Bioessays 1997; 19: 307-15.